ONT-380 is a small molecule HER2-selective tyrosine kinase inhibitor. It is an investigational drug for HER2-positive breast cancer. Cascadian Therapeutics has an exclusive license from Array BioPharma to manufacture, develop and commercialize ONT-380.
